618 related articles for article (PubMed ID: 17519900)
21. [Vascular and renal effects of anti-angiogenic therapy].
Halimi JM; Azizi M; Bobrie G; Bouché O; Deray G; des Guetz G; Lecomte T; Levy B; Mourad JJ; Nochy D; Oudard S; Rieu P; Sahali D
Nephrol Ther; 2008 Dec; 4(7):602-15. PubMed ID: 19027389
[TBL] [Abstract][Full Text] [Related]
22. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
[No Abstract] [Full Text] [Related]
23. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Patel TV; Morgan JA; Demetri GD; George S; Maki RG; Quigley M; Humphreys BD
J Natl Cancer Inst; 2008 Feb; 100(4):282-4. PubMed ID: 18270341
[No Abstract] [Full Text] [Related]
24. [Dermatologic side effects induced by new angiogenesis inhibitors].
Sibaud V; Garrido-Stowhas I; Cottura E; Chevreau C
Bull Cancer; 2011 Oct; 98(10):1221-9. PubMed ID: 22001771
[TBL] [Abstract][Full Text] [Related]
25. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
26. The role of antiangiogenesis therapy: bevacizumab and beyond.
Cortés-Funes H
Clin Transl Oncol; 2009 Jun; 11(6):349-55. PubMed ID: 19531449
[TBL] [Abstract][Full Text] [Related]
27. Targeted therapy in advanced non-small-cell lung cancer.
Gettinger S
Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
[TBL] [Abstract][Full Text] [Related]
28. [Cutaneous side effects of antiangiogenic agents].
Robert C
Bull Cancer; 2007 Jul; 94 Spec No():S260-4. PubMed ID: 17846013
[TBL] [Abstract][Full Text] [Related]
29. [Oral drugs inhibiting the VEGF pathway].
Ropert S; Mir O; Armand JP
Bull Cancer; 2007 Jul; 94 Spec No():S180-90. PubMed ID: 17846003
[TBL] [Abstract][Full Text] [Related]
30. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
[TBL] [Abstract][Full Text] [Related]
31. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Minor DR
J Clin Oncol; 2010 Oct; 28(30):e619; author reply e620. PubMed ID: 20733133
[No Abstract] [Full Text] [Related]
32. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
Walraven M; Witteveen PO; Lolkema MP; van Hillegersberg R; Voest EE; Verheul HM
Angiogenesis; 2011 May; 14(2):135-41. PubMed ID: 21188500
[TBL] [Abstract][Full Text] [Related]
34. Targeting angiogenesis in esophagogastric adenocarcinoma.
Okines AF; Reynolds AR; Cunningham D
Oncologist; 2011; 16(6):844-58. PubMed ID: 21632459
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Eisen T; Sternberg CN; Robert C; Mulders P; Pyle L; Zbinden S; Izzedine H; Escudier B
J Natl Cancer Inst; 2012 Jan; 104(2):93-113. PubMed ID: 22235142
[TBL] [Abstract][Full Text] [Related]
36. [Angiogenesis and renal cell carcinoma].
Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
[TBL] [Abstract][Full Text] [Related]
37. Vascular complications of selected cancer therapies.
Daher IN; Yeh ET
Nat Clin Pract Cardiovasc Med; 2008 Dec; 5(12):797-805. PubMed ID: 18852710
[TBL] [Abstract][Full Text] [Related]
38. Kidney cancer: Does hypothyroidism predict clinical outcome?
Rini B
Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
[No Abstract] [Full Text] [Related]
39. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Je Y; Schutz FA; Choueiri TK
Lancet Oncol; 2009 Oct; 10(10):967-74. PubMed ID: 19767240
[TBL] [Abstract][Full Text] [Related]
40. American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Kibble A; Shumoogam J
IDrugs; 2007 Aug; 10(8):509-12. PubMed ID: 17665319
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
